Just reported
From Illumina's results release of 29 октября 2026 г.; its quarterly report has since been filed.
Actual
1,13B $
+4,2 % y/y
-2,6 % q/q
Guided
—
No guide given
Actual
1,43 $
+46 % y/y
+5,9 % q/q
Guided
—
No guide given
Actual
305M $
+34 % y/y
+24 % q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Доли выручки — это оценки за quarter ended 2026-03-31, а не цифры из поданной отчётности.
NovaSeq X
A high-throughput DNA-sequencing machine used by customers that need to process large numbers of samples.
MiSeq i100
A lower-throughput DNA-sequencing machine for labs running smaller or more project-based batches.
NovaSeq 6000
A high-throughput DNA-sequencing machine that some customers continue to use alongside newer systems.
StrataMap Spatial
A sequencing-based workflow that helps researchers study biological activity in specific locations within tissue.
SomaScan and SomaSeq
Tools for measuring proteins and connecting protein measurements with genetic information.
Billion Cell Atlas
A large collection of data on how cells respond to genetic changes, sold to drug companies for biological research and drug discovery.
Полная финансовая отчётность →
Illumina makes machines that read DNA and sells the chemicals and other supplies customers use to run samples on them. Hospitals and clinical laboratories use sequencing for applications such as cancer testing, inherited-disease testing and screening; researchers and drug companies use it to study biology and develop medicines. Illumina also sells tools for measuring proteins and provides biological data and related services.
Построено по собственной отчётности Illumina, Inc., поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.
207,02 $-1,2 %закрытие 13 нояб.
Данные по 27 сентября 2026 г., из отчёта 10-Q, поданного 30 октября 2026 г.
Illumina sells DNA-sequencing kits and machines to medical laboratories, hospitals, universities and drug companies.
The themes Illumina is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A+
Полоса под ценой показывает оценку на каждую дату — только по отчётам, которые к тому моменту уже были опубликованы.
Показано 2 из 41 кварталов истории оценок компании Illumina, Inc.. Остальные 39 уходят к ноябрь 2016 г..
